InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,956.62
(
-0.48%
)
US TECH 100
20,418.80
(
-0.35%
)
Dow Jones
43,787.16
(
-0.39%
)
Brent Oil
71.96
(
0.13%
)
Bitcoin
88,696.45
(
-2.06%
)
Post# of 253595
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120722
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 178909

Thursday, 07/24/2014 5:41:34 PM

Thursday, July 24, 2014 5:41:34 PM

Post# of 253595
Pfenex (PFNX) IPOs 9.58M* shares @$6.00 (way below the originally anticipated range of $12-14) and finishes first day of trading at $5.30, down 12%:

http://finance.yahoo.com/news/pfenex-inc-announces-pricing-initial-042500107.html

Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases.

A Lucentis biosimilar strikes me as a dubious business proposition given the availability of dirt-cheap off-label Avastin. Perhaps that’s why PFNX’s enterprise value (<$100M) is so low.

*Assuming exercise of underwriter’s option.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up